SPY120 / Spyre Therap - LARVOL DELTA

Additionally, we are pleased to share new preclinical data demonstrating that each of our combination programs (α4β7 + TL1A, α4β7 + IL-23, and TL1A + IL-23) exhibit superior efficacy relative to constituent monotherapies in rodent TNBS-induced colitis models... (GlobeNewswire) - "The poster will be available for viewing during the UEGW Congress..."

Preclinical • Inflammatory Bowel Disease • Ulcerative Colitis

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn’s and Colitis Organisation (PRNewswire) - "Spyre Therapeutics, Inc...today announced a poster presentation at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO), held February 19-22, 2025, in Berlin, Germany, showing that combined inhibition of α4β7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis and coadministration demonstrates no drug-drug effects on exposure in non-human primates (NHPs)...'We are thrilled to share these recent preclinical findings supporting the combination potential for our SPY120 program...demonstrating that combined inhibition of the α4β7 integrin and TL1A cytokine provide additive or greater than additive efficacy relative to inhibition of either target alone,'...'We look forward to testing all three potential best-in-indication combinations in our Phase 2 trial in ulcerative colitis patients which is expected to begin mid-year.'"

New P2 trial • Preclinical • Inflammatory Bowel Disease • Ulcerative Colitis